PMID- 37974292
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231120
IS  - 2055-8260 (Print)
IS  - 2055-8260 (Electronic)
IS  - 2055-8260 (Linking)
VI  - 9
IP  - 1
DP  - 2023 Nov 16
TI  - Assessment HOMA as a predictor for new onset diabetes mellitus and diabetic 
      complications in non-diabetic adults: a KoGES prospective cohort study.
PG  - 7
LID - 10.1186/s40842-023-00156-3 [doi]
LID - 7
AB  - BACKGROUND: Homeostasis model assessment for insulin resistance (HOMA-IR) is a 
      biomarker for type 2 diabetes mellitus (T2DM). However, the role of HOMA-IR in 
      the non-diabetic is unclear. This study aimed to determine whether IR measured 
      HOMA-IR value is associated with new onset diabetes as well as vascular disease 
      and can be used as an early predictor for diabetes and vascular diseases in 
      non-diabetic participants. METHODS: From a prospective community-based cohort of 
      10,030 individuals, 4314 individuals younger than 65 years and without diabetes 
      were enrolled and divided into three groups by baseline HOMA-IR tertiles: low 
      (n = 1454), moderate (n = 1414), and high (n = 1446). The primary outcome was new 
      onset T2DM. Secondary outcomes were chronic kidney disease (CKD) and a composite 
      of coronary artery disease, myocardial infarction, and stroke as macrovascular 
      events. RESULTS: The mean age was 51 years. The prevalence of hypertension and 
      cholesterol and HbA1c were higher in the high HOMA-IR group. New onset T2DM 
      (5.8%) and CKD (12.2%) incidence in the high HOMA-IR group was higher than that 
      in the others. The prevalence of macrovascular events did not differ among 
      groups. High-HOMA-IR was an independent risk factor for new onset T2DM (odds 
      ratio 1.86 [1.17-2.96]; p = 0.01) and CKD (1.49 [1.12-1.98]; p = 0.01). 
      CONCLUSIONS: High HOMA-IR was an early predictor of new onset T2DM and CKD, 
      regardless of HbA1c in non-diabetic individuals. Further research on the specific 
      cut off value will be needed.
CI  - (c) 2023. The Author(s).
FAU - Lee, Jibeom
AU  - Lee J
AD  - Department of Biomedical Science and Engineering, Gwangju Institute of Science 
      and Technology, Gwangju, Republic of Korea.
FAU - Kim, Moon-Hyun
AU  - Kim MH
AD  - Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University 
      College of Medicine, Seoul, Republic of Korea.
FAU - Jang, Ji-Yong
AU  - Jang JY
AUID- ORCID: 0000-0003-2842-7500
AD  - Division of Cardiology, National Health Insurance Service Ilsan hospital, Goyang, 
      Republic of Korea. dogkkoma@gmail.com.
FAU - Oh, Chang-Myung
AU  - Oh CM
AD  - Department of Biomedical Science and Engineering, Gwangju Institute of Science 
      and Technology, Gwangju, Republic of Korea. cmoh@gist.ac.kr.
LA  - eng
PT  - Journal Article
DEP - 20231116
PL  - England
TA  - Clin Diabetes Endocrinol
JT  - Clinical diabetes and endocrinology
JID - 101669619
PMC - PMC10652621
OTO - NOTNLM
OT  - Chronic kidney disease
OT  - Diabetes mellitus
OT  - HOMA-IR
OT  - Insulin resistance
COIS- The authors declare no conflict of interest.
EDAT- 2023/11/17 15:27
MHDA- 2023/11/17 15:28
PMCR- 2023/11/16
CRDT- 2023/11/17 02:00
PHST- 2022/11/10 00:00 [received]
PHST- 2023/11/06 00:00 [accepted]
PHST- 2023/11/17 15:28 [medline]
PHST- 2023/11/17 15:27 [pubmed]
PHST- 2023/11/17 02:00 [entrez]
PHST- 2023/11/16 00:00 [pmc-release]
AID - 10.1186/s40842-023-00156-3 [pii]
AID - 156 [pii]
AID - 10.1186/s40842-023-00156-3 [doi]
PST - epublish
SO  - Clin Diabetes Endocrinol. 2023 Nov 16;9(1):7. doi: 10.1186/s40842-023-00156-3.